Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 10, 2017, Pages 2775-2781

  Brennan Krohn, Thea ^a,b   Truelson, Katherine A ^a,c   Smith, Kenneth P ^a   Kirby, James E ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CHLORAMPHENICOL; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; FOSFOMYCIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; RIFAMPICIN; SULFAMETHOXAZOLE; TRIMETHOPRIM; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL STRAIN; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CONTROLLED STUDY; DRUG POTENTIATION; FRACTIONAL INHIBITORY CONCENTRATION INDEX; MEASUREMENT ACCURACY; MEDICAL TECHNOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; AUTOMATION; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DEVICES; DRUG EFFECT; HUMAN; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PHARMACEUTICS; PROCEDURES;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; AUTOMATION; AZTREONAM; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; RIFAMPIN; TECHNOLOGY, PHARMACEUTICAL;

EID: 85030721495     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx241     Document Type: Article

References (46)

1. Temkin E, Adler A, Lerner A et al. Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. Ann NY Acad Sci 2014; 1323: 22-42
2. Zusman O, Avni T, Leibovici L et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 2013; 57: 5104-11
3. Paul M, Carmeli Y, Durante-Mangoni E et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2014; 69: 2305
4. Rafailidis PI, Falagas ME. Options for treating carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis 2014; 27: 479-83
5. Clock SA, Tabibi S, Alba L et al. In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2013; 76: 343-6
6. Hirsch EB, Guo B, Chang KT et al. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. J Infect Dis 2013; 207: 786-93
7. Tängdén T, Hickman RA, Forsberg P et al. Evaluation of double-and tripleantibiotic combinations for VIM-and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother 2014; 58: 1757-62
8. Tascini C, Tagliaferri E, Giani T et al. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2013; 57: 3990-3
9. Smith KP, Brennan-Krohn T, Weir S et al. Improved accuracy of cefepime susceptibility testing for ESBL-producing Enterobacteriaceae using an on-demand digital dispensing method. J Clin Microbiol 2016; 55: 470-8
10. Smith KP, Kirby JE. How inkjet printing technology can defeatmultidrugresistant pathogens. Future Microbiol 2016; 11: 1375-7
11. Smith KP, Kirby JE. Verification of an automated, digital dispensing platform for at-will brothmicrodilution-based antimicrobial susceptibility testing. J ClinMicrobiol 2016; 54: 2288-93
12. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Sixth Informational Supplement M100-S26. CLSI, Wayne, PA, USA, 2016
13. Hindler JA, Humphries RM. Colistin MIC variability bymethod for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli. J Clin Microbiol 2013; 51: 1678-84
14. Sutherland CA, Nicolau DP. To add or not to add polysorbate 80: impact on colistin MICs for clinical strains of Enterobacteriaceae and Pseudomonas aeruginosa and quality controls. J ClinMicrobiol 2014; 52: 3810
15. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Tenth Edition: Approved Standard M07-A10. CLSI, Wayne, PA, USA, 2015
16. Elion GB, Singer S, Hitchings GH. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. JBiolChem 1954; 208: 477-88
17. EUCAST. Clinical Breakpoints. http://www.eucast.org/clinical_breakpoints/
18. Henwood CJ, Gatward T,WarnerMet al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479-87
19. Tan TY, Ng LS, Poh K. Susceptibility testing of unconventional antibiotics against multiresistant Acinetobacter spp. by agar dilution and Vitek 2. Diagn Microbiol Infect Dis 2007; 58: 357-61
20. Clark R, Lewinski M, Loeffelholz M et al. Cumitech 31A, Verification and Validation of Procedures in the Clinical Microbiology Laboratory. Washington, DC: ASM Press, 2009
21. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1
22. Bratu S, Tolaney P, Karumudi U et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005; 56: 128-32
23. Elemam A, Rahimian J, Doymaz M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J ClinMicrobiol 2010; 48: 3558-62
24. Jernigan MG, Press EG, Nguyen MH et al. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2012; 56: 3395-8
25. Pankey GA, Ashcraft DS. Detection of synergy using the combination of polymyxin B with either meropenem or rifampin against carbapenemaseproducing Klebsiella pneumoniae. DiagnMicrobiol Infect Dis 2011; 70: 561-4
26. Pogue JM, Neelakanta A, Mynatt RP et al. Carbapenem-resistance in Gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the DetroitMedical Center. Clin Infect Dis 2014; 59: S388-93
27. Thaden JT, Pogue JM, Kaye KS. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence 2017; 8: 403-16
28. Ni W, Han Y, Liu J et al. Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore) 2016; 95: e3126
29. Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis 2014; 59: S374-80
30. DoanTL, FungHB,MehtaDet al. Tigecycline: a glycylcyclineantimicrobial agent. Clin Ther 2006; 28: 1079-106
31. Wyeth Pharmaceuticals. TygacilVR (Tigecycline) for Injection, Package Insert. Philadelphia, PA, USA, 2010
32. Muralidharan G, Micalizzi M, Speth J et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-9
33. The Medicines Company. MINOCINVR (Minocycline) for Injection, Package Insert. Parsippany, NJ, USA, 2015
34. Guh AY, Bulens SN, Mu Y et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012-2013. JAMA 2015; 314: 1479-87
35. Poirel L, Kieffer N, Nordmann P. In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 2016; 71: 156-61
36. Oliva A, Gizzi F, Mascellino MT et al. Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae. Clin Microbiol Infect 2016; 22: 147-53
37. Berçot B, Poirel L, Dortet L et al. In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae. J Antimicrob Chemother 2011; 66: 2295-7
38. Albiero J, Sy SKB, Mazucheli J et al. Pharmacodynamic evaluation of the potential clinical utility of fosfomycin and meropenem in combination therapy against KPC-2-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2016; 60: 4128-39
39. Morrill HJ, Pogue JM, Kaye KS et al. Treatment options for carbapenemresistant Enterobacteriaceae infections. Open Forum Infect Dis 2015; 2: ofv050
40. Daikos GL,Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011; 17: 1135-41
41. AlvesMD, Ribeiro VB, Tessari JP et al. Effect of cefepime dose onmortality of patients with Gram-negative bacterial bloodstreaminfections: a prospective cohort study. JAntimicrobChemother 2014; 69: 1681-7
42. US FDA. Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems. Rockville,MD: US FDA, 2009
43. Fuchs PC, Barry AL, Brown SD. Susceptibility testing quality control studies with fosfomycin tromethamine. Eur J Clin Microbiol Infect Dis 1997; 16: 538-40
44. Queenan AM, Foleno B, Gownley C et al. Effects of inoculum and β-lactamase activity in AmpC-and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBLmethodology. J ClinMicrobiol 2004; 42: 269-75
45. Doern CD. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. JClinMicrobiol 2014; 52: 4124-8
46. Humphries RM, Testing: broth microdilution checkerboard and broth macrodilution methods. In: AL Leber, ed. Clinical Microbiology Procedures Handbook. Washington, DC: American Society of Microbiology, 2016; 5.16.1-5.8.23